Sienna Biopharmaceuticals (SNNA) expects to raise $64 million in an initial public offering (IPO) on Thursday, July 27th, IPO Scoop reports. The company will issue 4,300,000 shares at a price of $14.00-$16.00 per share.
Sienna Biopharmaceuticals has a market cap of $298.2 million.
J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.
Sienna Biopharmaceuticals provided the following description of their company for its IPO: “We are a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Our objective is to develop our multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology patients. We are advancing multiple product candidates derived from our Topical by Design™ platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. “.
Sienna Biopharmaceuticals was founded in 2010 and has 40 employees. The company is located at 30699 Russell Ranch Road, Suite 140, Westlake Village, California 91362, US and can be reached via phone at (818) 629-2256 or on the web at http://www.SiennaBio.com.
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
